-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $40

Benzinga·12/09/2025 18:23:32
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $34 to $40.